ERBB2 and breast carcinoma: In terms of histology and molecular subtype, we also tested for differences in macrophage composition between lung adenocarcinomas (LUAD) and lung squamous cell carcinomas (LUSC), as well as between breast cancers with varying receptor status, including HR + , HER2 + , HR + /HER2+ and triple negative breast cancers (TNBC).